• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » J&J, Google’s Verily partner to form robotic-platform developer Verb Surgical

J&J, Google’s Verily partner to form robotic-platform developer Verb Surgical

December 10, 2015 By Fink Densford

Johnson & Johnson, Ethicon, VerilyJohnson & Johnson (NYSE:JNJ) said today it is partnering with newly-titled Verily Life Sciences, formerly Google Life Sciences, to form Verb Surgical, which aims to develop a robotic surgical platform.

Verb Surgical aims to develop a comprehensive surgical platform that incorporates “leading edge” robotic capabilities and medical technology for use in the operating room, according to Johnson & Johnson. The company plans to develop them in partnership with surgeons and hospitals with a goal of “greater hospital efficiency.”

The new company comes from a strategic collaboration between J&J med device company Ethicon and Google Life Sciences announced in March, and will be headed by Scott Huennekens, Johnson & Johnson said.

Huennekens previously served as CEO of Volcano Corp., which was bought by Royal Philips (NYSE:PHG) in February this year for $1.2 billion. Before that, Huennekens served as CEO of Digirad and held senior positions at Baxter. Huennekens serves as a board member at EndoChoice, Reva Medical, Sonendo and the Medical Device Manufacturer’s Assn.

“I’m very excited about the possibilities that we can realize through our new surgical solutions company. By maximizing the distinct capabilities of these 2 market-leading companies, we aim to develop novel technologies and solutions to help improve the standard of care around the world. Our name speaks for itself. We are a company dedicated to action and to making a difference in people’s lives, in partnership with surgeons globally,” Huennekens said in prepared remarks.

Surgical instruments for the robot-assisted platform will come from Ethicon, J&J said, and the company is being supported by Ethicon, J&J Innovation and Verily, with intellectual contributions and in-process R&D assets coming from Ethicon and Verily.

“We believe Verb Surgical has the potential to change the future of surgery, not just robotic surgery. The team has already made meaningful progress on the robotics platform, which is being developed for application across a host of surgical specialties,” J&J med device worldwide chair Gary Pruden said in a press release.

The new biz is slated to be headquartered in Mountain View, Calif., with a board including members from all involved companies.

Filed Under: Business/Financial News, Surgical Robotics Tagged With: Ethicon, Johnson and Johnson, Verily

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy